Question 1

What are the most cited papers from XLV Diagnostics (Canada)?

Accepted Answer

The most cited paper from XLV Diagnostics (Canada) is "Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis" (Mark Lebwohl et al., 2015), with 826 citations. Next come "Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)" (210) and "Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment ( SCULPTURE Extension Study)" (200).

Question 2

Which research topics does XLV Diagnostics (Canada) publish most on?

Accepted Answer

By volume in 2022-now: Dermatology and Skin Diseases, Nail Diseases and Treatments, Cutaneous lymphoproliferative disorders research and CAR-T cell therapy research.

Question 3

Which fields of science does XLV Diagnostics (Canada) work in?

Accepted Answer

In all years, 75% of research at XLV Diagnostics (Canada) is in Health Sciences, 25% in Life Sciences. Its largest fields are Medicine (75%), Immunology and Microbiology (18%), Biochemistry, Genetics and Molecular Biology (7%). It does 1.4× the world's share of Health Sciences.

Question 4

Is XLV Diagnostics (Canada)'s research output growing?

Accepted Answer

Output in 2022-2025 was 420% higher than in 2018-2021.